IP Library Granted Patent US 8,344,162
Granted Patent B2
US 8,344,162 · App. 13/297,846 · Granted Jan 1, 2013

Synthetic processes for the preparation of aminocyclohexyl ether compounds

Assignee: Cardiome Pharma Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,344,162
App. No.
13/297,846
Granted
Jan 1, 2013
Kind
B2
Abstract

This invention is directed to stereoselective synthesis of compounds of formula (I) or formula (II): or a pharmaceutically acceptable salt, ester, amide, complex, chelate, clathrate, solvate, polymorph, stereoisomer, metabolite or prodrug thereof; wherein R 3 , R 4 and R 5 are defined herein. Compounds of formula (I) and formula (II) are known to be useful in treating arrhythmias.

Claims (25)

1. A method of making a compound of formula (I):

or a pharmaceutically acceptable salt, ester, amide, clathrate with a cyclodextrin or solvate in a solution phase thereof; or a single stereoisomer or mixture thereof;

wherein:

R 3 , R 4 and R 5 are independently bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, cyano, sulfamyl, trifluoromethyl, —CHF 2 , —SO 2 N(R 8 )R 9 , —OCF 3 , C 2 -C 7 alkanoyloxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 7 -C 12 aralkoxy, C 2 -C 7 alkoxycarbonyl, C 1 -C 6 thioalkyl, aryl or —N(R 6 )R 7 ; and

R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen, acetyl, methanesulfonyl or C 1 -C 6 alkyl;

which method comprises the following:

a) reacting a compound of formula (1a):

 with a compound of formula (2a):

 under suitable condensation conditions to form a product;

b) reacting the product of a) with a compound of formula (5):

 wherein Q is a leaving group and R 3 , R 4 and R 5 are as defined above, under suitable ether coupling conditions to form a product;

c) reacting the product of b) under suitable cyclization conditions to form a compound of formula (6):

 wherein each R 2a is O or H 2 where at least one R 2a is O, R is H, C 2 -C 5 acyl or an oxygen-protecting group and R 3 , R 4 and R 5 are as defined above; and

d) reducing the compound of formula (6) under suitable conditions to form a compound of formula (I), as set forth above;

e) optionally treating the compound of formula (I) with a suitable reagent or solvent to form the pharmaceutically acceptable salt, ester, amide, clathrate with a cyclodextrin or solvate in a solution phase thereof.

2. The method of claim 1 wherein the product of a) comprises a compound of formula (9), a compound of formula (10) or a mixture of a compound of formula (9) and a compound of formula (10):

where each R 2a is O or H 2 and R is H, C 2 -C 5 acyl or an oxygen-protecting group.

3. The method of claim 1 or claim 2 wherein the product of b) comprises a compound of formula (11), a compound of formula (12) or a mixture of a compound of formula (11) and a compound of formula (12):

where each R 2a is O or H 2 , R is H, C 2 -C 5 acyl or an oxygen-protecting group and R 3 , R 4 and R 5 are as defined above.

4. The method of claim 1 further comprising the formation of an acid addition salt of the compound of formula (I).

5. The method of claim 1 wherein the compound of formula (I) is a compound of formula (I) where R 3 , R 4 and R 5 are independently hydrogen, hydroxy or C 1 -C 6 alkoxy; with the proviso that R 3 , R 4 and R 5 cannot all be hydrogen at the same time.

6. The method of claim 5 wherein the compound of formula (I) is a compound of formula (Ia):

or a pharmaceutically acceptable salt, ester, amide, clathrate with a cyclodextrin or solvate in a solution phase thereof.

7. The method of claim 5 wherein the compound of formula (I) is selected from the group consisting of:

or pharmaceutically acceptable salts, esters, amides, clathrates with cyclodextrin or solvates in solution phase thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: JUNG, GRACE; YEE, JAMES GEE KEN; CHOU, DOUG TA HUNG; PLOUVIER, BERTRAND M.C.
To: CARDIOME PHARMA CORP.
Reel/Frame 052085/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
Continuity (6)
Division 12709355 · Feb 19, 2010
Division 11455280 · Jun 15, 2006
Provisional Application 60748248 · Dec 7, 2005
Provisional Application 60690989 · Jun 15, 2005
Related Publication 20120065408A1 · Mar 15, 2012
Related Publication 20120271057A9 · Oct 25, 2012